carbonic anhydrase IX peptide-pulsed dendritic cells

Carbonic anhydrase IX peptide-pulsed dendritic cells are an experimental form of cellular immunotherapy designed primarily for the treatment of renal cell carcinoma and other CA9-expressing tumors. This therapy involves isolating dendritic cells from a patient or donor, loading (pulsing) them with peptides derived from the cancer-associated antigen carbonic anhydrase IX (CA9), and re-infusing the modified dendritic cells into the patient. The pulsed dendritic cells act as potent antigen-presenting cells, promoting a T cell-mediated anti-tumor immune response specifically against cells expressing the CA9 antigen. CA9 is a membrane protein overexpressed in >80% of renal cell carcinoma (RCC) and serves as a tumor-specific marker[1][3][7]. The rationale is that DCs pulsed with CA9 peptides elicit cytotoxic T lymphocyte (CTL) and helper T cell responses capable of targeting and killing CA9-expressing tumor cells. Preclinical and limited clinical studies suggest that such vaccines can generate specific immune responses and may suppress tumor growth in RCC and potentially other CA9-positive cancers[1][3][5][6].

Other names

CA9 peptide-pulsed dendritic cellsCA-9 peptide-pulsed dendritic cellsCA 9 peptide-pulsed dendritic cellsCA9-pulsed DC vaccineCA-9-pulsed DC vaccineCA 9-pulsed DC vaccinecarbonic anhydrase IX peptide dendritic cell vaccine